{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:31:06Z","timestamp":1791855066283,"version":"4.3.4"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.pharmthera.2018.05.010","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T02:28:22Z","timestamp":1527215302000},"page":"148-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":207,"special_numbering":"C","title":["The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?"],"prefix":"10.1016","volume":"190","author":[{"given":"Chadi G.","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Duman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2018.05.010_bb20185","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.biopsych.2017.01.002","article-title":"What's the Buzz About Hydroxynorketamine? Is It the History, the Story, the Debate, or the Promise?","volume":"81","author":"Abdallah","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/da.22501","article-title":"Ketamine's mechanism of action: A path to rapid-acting antidepressants","volume":"33","author":"Abdallah","year":"2016","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0010","first-page":"566","article-title":"Prefrontal connectivity and glutamate transmission: Relevance to depression pathophysiology and ketamine treatment","volume":"2","author":"Abdallah","year":"2017","journal-title":"Biological Psychiatry: Cognitive Neuroscience and Neuroimaging"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0015","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/npp.2016.186","article-title":"Ketamine treatment and global brain connectivity in major depression","volume":"42","author":"Abdallah","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/nyas.12718","article-title":"Ketamine as a promising prototype for a new generation of rapid-acting antidepressants","volume":"1344","author":"Abdallah","year":"2015","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0025","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.euroneuro.2012.05.009","article-title":"A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD","volume":"23","author":"Abdallah","year":"2013","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0030","first-page":"S111","article-title":"Ketamine, but not the NMDA receptor antagonist lanicemine, increases prefrontal connectivity in depressed patients","volume":"43","author":"Abdallah","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0035","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/npp.2017.49","article-title":"The nucleus accumbens and ketamine treatment in major depressive disorder","volume":"42","author":"Abdallah","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0040","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.euroneuro.2015.04.025","article-title":"Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder","volume":"25","author":"Abdallah","year":"2015","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neulet.2017.04.046","article-title":"Neurobiology of posttraumatic stress disorder (PTSD): A path from novel pathophysiology to innovative therapeutics","volume":"649","author":"Abdallah","year":"2017","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.12","article-title":"Anterior hippocampal dysconnectivity in posttraumatic stress disorder: A dimensional and multimodal approach","volume":"7","author":"Abdallah","year":"2017","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0055","doi-asserted-by":"crossref","DOI":"10.1177\/2470547018758043","article-title":"The role of stress in the pathogenesis and maintenance of obsessive-compulsive disorder","volume":"2","author":"Adams","year":"2018","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0060","doi-asserted-by":"crossref","DOI":"10.1177\/2470547017724069","article-title":"The association of PTSD symptom severity with localized Hippocampus and amygdala abnormalities","volume":"1","author":"Akiki","year":"2017","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0065","article-title":"Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression","volume":"79","author":"Albott","year":"2018","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0070","doi-asserted-by":"crossref","DOI":"10.1177\/2470547017743511","article-title":"Hydroxynorketamine: Implications for the NMDA receptor hypothesis of ketamine's antidepressant action","volume":"1","author":"Aleksandrova","year":"2017","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0075","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archpsyc.57.3.270","article-title":"Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists","volume":"57","author":"Anand","year":"2000","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0080","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.biopsych.2012.07.031","article-title":"Global prefrontal and fronto-amygdala dysconnectivity in bipolar I disorder with psychosis history","volume":"73","author":"Anticevic","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0085","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.biopsych.2014.07.022","article-title":"N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia","volume":"77","author":"Anticevic","year":"2015","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0090","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.biopsych.2013.10.021","article-title":"Global resting-state functional magnetic resonance imaging analysis identifies frontal cortex, striatal, and cerebellar dysconnectivity in obsessive-compulsive disorder","volume":"75","author":"Anticevic","year":"2014","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0095","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0100","doi-asserted-by":"crossref","DOI":"10.1177\/2470547017724714","article-title":"Combat exposure severity is associated with reduced cortical thickness in combat veterans: A preliminary report","volume":"1","author":"Averill","year":"2017","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neulet.2016.11.064","article-title":"Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies","volume":"649","author":"Averill","year":"2017","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.31887\/DCNS.2006.8.3\/tban","article-title":"The role of serendipity in drug discovery","volume":"8","author":"Ban","year":"2006","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0115","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/mp.2008.106","article-title":"Glial pathology in an animal model of depression: Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole","volume":"15","author":"Banasr","year":"2010","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0125","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","article-title":"Effects of ketamine in treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bloch","year":"2012","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0130","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/da.22505","article-title":"Ketamine for treatment-resistant unipolar and bipolar major depression: Critical review and implications for clinical practice","volume":"33","author":"Bobo","year":"2016","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0135","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/ajp.154.6.805","article-title":"Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers","volume":"154","author":"Breier","year":"1997","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0140","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1176\/ajp.152.7.973","article-title":"MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder","volume":"152","author":"Bremner","year":"1995","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0145","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1152\/jn.91111.2008","article-title":"Stress-induced changes in nucleus accumbens glutamate synaptic plasticity","volume":"101","author":"Campioni","year":"2009","journal-title":"Journal of Neurophysiology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.116.235838","article-title":"Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters","volume":"359","author":"Can","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0155","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","author":"Canuso","year":"2018","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0160","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11713","article-title":"Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons","volume":"493","author":"Chaudhury","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0165","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/jcbfm.2008.78","article-title":"Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus","volume":"28","author":"Chowdhury","year":"2008","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0170","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.biopsych.2011.11.006","article-title":"1H-[13C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism","volume":"71","author":"Chowdhury","year":"2012","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0175","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/mp.2016.34","article-title":"Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects","volume":"22","author":"Chowdhury","year":"2017","journal-title":"Mol Psychiatry.Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0180","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1523\/JNEUROSCI.4763-10.2011","article-title":"IkappaB kinase regulates social defeat stress-induced synaptic and behavioral plasticity","volume":"31","author":"Christoffel","year":"2011","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0185","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/npp.2012.121","article-title":"Effects of inhibitor of kappaB kinase activity in the nucleus accumbens on emotional behavior","volume":"37","author":"Christoffel","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0190","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00000542-197310000-00003","article-title":"Distribution in the brain and metabolism of ketamine in the rat after intravenous administration","volume":"39","author":"Cohen","year":"1973","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0195","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopsych.2011.02.010","article-title":"Variable global dysconnectivity and individual differences in schizophrenia","volume":"70","author":"Cole","year":"2011","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0200","doi-asserted-by":"crossref","DOI":"10.1177\/2470547018768450","article-title":"Early life stress associated with increased striatal N-acetyl-aspartate (NAA): Cerebrospinal fluid (CSF) corticotropin-releasing factor (CRF) concentrations, hippocampal volume, body mass and behavioral correlates","volume":"2","author":"Coplan","year":"2018","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0205","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1464-410X.2008.08146_2.x","article-title":"The destruction of the lower urinary tract by ketamine abuse: A new syndrome?","volume":"102","author":"Cottrell","year":"2008","journal-title":"BJU International"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0210","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1176\/ajp.115.11.1025","article-title":"Cyloserine as an antidepressant agent","volume":"Vol. 115","author":"Crane","year":"1959","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0215","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0220","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/schbul\/sbu189","article-title":"Schizophrenia in the spectrum of gene-stress interactions: The FKBP5 example","volume":"41","author":"Daskalakis","year":"2015","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0225","doi-asserted-by":"crossref","DOI":"10.1177\/2470547017710916","article-title":"Neurobiology of chronic stress-related psychiatric disorders: Evidence from molecular imaging studies","volume":"1","author":"Davis","year":"2017","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0230","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archgenpsychiatry.2007.37","article-title":"Glutamate and the neural basis of the subjective effects of ketamine: A pharmaco-magnetic resonance imaging study","volume":"65","author":"Deakin","year":"2008","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0235","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.biopsych.2014.06.024","article-title":"In vivo ketamine-induced changes in [(11)C]ABP688 binding to metabotropic glutamate receptor subtype 5","volume":"77","author":"DeLorenzo","year":"2015","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0240","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pnpbp.2015.02.015","article-title":"Role of calcium, glutamate and NMDA in major depression and therapeutic application","volume":"64","author":"Deutschenbaur","year":"2016","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0245","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0250","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.biopsych.2012.09.031","article-title":"Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: A review","volume":"73","author":"Drevets","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0255","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/mp.2012.194","article-title":"Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans","volume":"18","author":"Driesen","year":"2013","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0260","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1038\/npp.2013.170","article-title":"The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity","volume":"38","author":"Driesen","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0265","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1034\/j.1399-5618.2002.01203.x","article-title":"Antidepressants and neuroplasticity","volume":"4","author":"D'Sa","year":"2002","journal-title":"Bipolar Disorders"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0270","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.1222939","article-title":"Synaptic dysfunction in depression: Potential therapeutic targets","volume":"338","author":"Duman","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0275","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0280","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/archpsyc.1997.01830190015002","article-title":"A molecular and cellular theory of depression","volume":"54","author":"Duman","year":"1997","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0285","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/mp.2017.58","article-title":"Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [(11)C]ABP688 and PET imaging study in depression","volume":"23","author":"Esterlis","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0290","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: A randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0295","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1126\/science.2549634","article-title":"Limbic seizures increase neuronal production of messenger RNA for nerve growth factor","volume":"245","author":"Gall","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0300","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.biopsych.2017.06.017","article-title":"Activity-dependent brain-derived neurotrophic factor release is required for the rapid antidepressant actions of scopolamine","volume":"83","author":"Ghosal","year":"2018","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0305","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0269881117705089","article-title":"Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders","volume":"31","author":"Glue","year":"2017","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0310","doi-asserted-by":"crossref","DOI":"10.1177\/2470547017736038","article-title":"The neurobiology of panic: A chronic stress disorder","volume":"1","author":"Goddard","year":"2017","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0315","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: A midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0320","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2470547017697317","article-title":"Rapid acting antidepressants in chronic stress models: Molecular and cellular mechanisms","volume":"1","author":"Hare","year":"2017","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0330","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biopsych.2014.06.020","article-title":"In vivo hippocampal subfield volumes in schizophrenia and bipolar disorder","volume":"77","author":"Haukvik","year":"2015","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0335","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: Evidence and potential mechanisms","author":"Ivan Ezquerra-Romano","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0345","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.mp.4001551","article-title":"Glutamate as a therapeutic target in psychiatric disorders","volume":"9","author":"Javitt","year":"2004","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0350","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1001\/jamapsychiatry.2017.3572","article-title":"Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: A randomized clinical trial","volume":"75","author":"Javitt","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0355","doi-asserted-by":"crossref","first-page":"8688","DOI":"10.1523\/JNEUROSCI.6078-08.2009","article-title":"Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation","volume":"29","author":"Jourdi","year":"2009","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0360","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.brainres.2005.02.032","article-title":"AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist","volume":"1042","author":"Karasawa","year":"2005","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0365","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s12035-012-8365-7","article-title":"Stress-induced grey matter loss determined by MRI is primarily due to loss of dendrites and their synapses","volume":"47","author":"Kassem","year":"2013","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0370","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archgenpsychiatry.2011.60","article-title":"Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder","volume":"68","author":"Kempton","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0375","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.15lr10272","article-title":"Low-dose d-cycloserine for depression?","volume":"77","author":"Kim","year":"2016","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0380","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jama.299.9.1063","article-title":"The loss of serendipity in psychopharmacology","volume":"299","author":"Klein","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0385","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/mp.2017.190","article-title":"The effects of ketamine on dopaminergic function: Meta-analysis and review of the implications for neuropsychiatric disorders","volume":"23","author":"Kokkinou","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0390","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature07455","article-title":"The molecular neurobiology of depression","volume":"455","author":"Krishnan","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0395","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11920-017-0829-z","article-title":"Synaptic loss and the pathophysiology of PTSD: Implications for ketamine as a prototype novel therapeutic","volume":"19","author":"Krystal","year":"2017","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0400","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-004-1982-8","article-title":"Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects","volume":"179","author":"Krystal","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0405","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/11533230-000000000-00000","article-title":"Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists","volume":"24","author":"Krystal","year":"2010","journal-title":"CNS Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2018.05.010_bb0410","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/sj.mp.4001021","article-title":"Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments","volume":"7","author":"Krystal","year":"2002","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0415","doi-asserted-by":"crossref","DOI":"10.1177\/2470547017698140","article-title":"Neuroclinical framework for the role of stress in addiction","volume":"1","author":"Kwako","year":"2017","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0420","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/jnnp.74.7.962","article-title":"Similarity and disparity of obsessive-compulsive disorder and schizophrenia in MR volumetric abnormalities of the hippocampus-amygdala complex","volume":"74","author":"Kwon","year":"2003","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0425","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0430","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1523\/JNEUROSCI.20-01-00008.2000","article-title":"Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons","volume":"20","author":"Lauterborn","year":"2000","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0435","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuropharm.2016.09.011","article-title":"Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures","volume":"111","author":"Lepack","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0440","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu033","article-title":"BDNF release is required for the behavioral actions of ketamine","volume":"18","author":"Lepack","year":"2015","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0445","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1017\/S1461145710001082","article-title":"Brain-derived neurotrophic factor signalling mediates antidepressant effects of lamotrigine","volume":"14","author":"Li","year":"2011","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0450","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0455","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/mp.2017.85","article-title":"Uncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects","volume":"23","author":"Li","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0460","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0028-3908(00)00194-5","article-title":"Antidepressant-like actions of an AMPA receptor potentiator (LY392098)","volume":"40","author":"Li","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0465","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/npp.2016.202","article-title":"GLYX-13 produces rapid antidepressant responses with key synaptic and behavioral effects distinct from ketamine","volume":"42","author":"Liu","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0470","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.biopsych.2011.09.030","article-title":"Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex","volume":"71","author":"Liu","year":"2012","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0475","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2015.12.001","article-title":"New targets for rapid antidepressant action","volume":"152","author":"Machado-Vieira","year":"2017","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0480","doi-asserted-by":"crossref","DOI":"10.1177\/2470547017713297","article-title":"Post-traumatic stress disorder: The relationship between the fear response and chronic stress","volume":"1","author":"Maeng","year":"2017","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0485","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0490","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/87865","article-title":"The cellular neurobiology of depression","volume":"7","author":"Manji","year":"2001","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0495","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1038\/npp.2017.106","article-title":"A randomized, double-blind, placebo-controlled, sequential parallel comparison design trial of adjunctive riluzole for treatment-resistant major depressive disorder","volume":"42","author":"Mathew","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0500","doi-asserted-by":"crossref","DOI":"10.1177\/2470547017710764","article-title":"Preclinical and clinical evidence of DNA methylation changes in response to trauma and chronic stress","volume":"1","author":"Matosin","year":"2017","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0505","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev.neuro.22.1.105","article-title":"Stress and hippocampal plasticity","volume":"22","author":"McEwen","year":"1999","journal-title":"Annual Review of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1314.001","article-title":"Protection and damage from acute and chronic stress: Allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders","volume":"1032","author":"McEwen","year":"2004","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0515","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1017\/S0033291714001603","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"45","author":"McGirr","year":"2015","journal-title":"Psychological Medicine"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0520","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.66","article-title":"The positive effect on ketamine as a priming adjuvant in antidepressant treatment","volume":"5","author":"Melo","year":"2015","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0525","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/mp.2015.83","article-title":"A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder","volume":"21","author":"Milak","year":"2016","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0530","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neuropharm.2015.07.028","article-title":"Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition","volume":"100","author":"Miller","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0535","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.157","article-title":"The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats","volume":"3","author":"Moaddel","year":"2015","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0540","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1471-4159.1993.tb13387.x","article-title":"Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: Comparison to hippocampus and basal ganglia","volume":"60","author":"Moghaddam","year":"1993","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0545","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0550","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","article-title":"Ketamine use: A review","volume":"107","author":"Morgan","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0555","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neuroscience.2012.04.041","article-title":"Stress during development alters dendritic morphology in the nucleus accumbens and prefrontal cortex","volume":"216","author":"Muhammad","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0560","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/hbm.23235","article-title":"Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder","volume":"37","author":"Murrough","year":"2016","journal-title":"Human Brain Mapping"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0565","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrd.2017.16","article-title":"Targeting glutamate signalling in depression: Progress and prospects","volume":"16","author":"Murrough","year":"2017","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0570","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0575","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1523\/JNEUROSCI.15-11-07539.1995","article-title":"Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments","volume":"15","author":"Nibuya","year":"1995","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0580","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.pain.2011.03.026","article-title":"Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases","volume":"152","author":"Noppers","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0585","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn3504","article-title":"NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease","volume":"14","author":"Paoletti","year":"2013","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0590","doi-asserted-by":"crossref","DOI":"10.1177\/2470547017703993","article-title":"The neurobiological mechanisms of generalized anxiety disorder and chronic stress","volume":"1","author":"Patriquin","year":"2017","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0595","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/0896-6273(92)90067-N","article-title":"Neurotrophin expression in rat hippocampal slices: A stimulus paradigm inducing LTP in CA1 evokes increases in BDNF and NT-3 mRNAs","volume":"9","author":"Patterson","year":"1992","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0600","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/ALN.0000000000000285","article-title":"(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function","volume":"121","author":"Paul","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0605","article-title":"Common neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant-like effects","author":"Pham","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0610","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamapsychiatry.2014.2470","article-title":"Amygdala-hippocampal volume and the phenotypic heterogeneity of posttraumatic stress disorder: A cross-sectional study","volume":"72","author":"Pietrzak","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0615","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn3138","article-title":"The stressed synapse: The impact of stress and glucocorticoids on glutamate transmission","volume":"13","author":"Popoli","year":"2012","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0620","doi-asserted-by":"crossref","DOI":"10.1177\/2470547018768771","article-title":"Altered cortical gamma-amino butyric acid in female veterans with suicidal behavior: Sex differences and clinical correlates","volume":"2","author":"Prescot","year":"2018","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0625","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/01.pra.0000462606.17725.93","article-title":"Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent","volume":"21","author":"Preskorn","year":"2015","journal-title":"Journal of Psychiatric Practice"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0630","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","article-title":"An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder","volume":"28","author":"Preskorn","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0635","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbr.2013.08.041","article-title":"Ketamine and imipramine in the nucleus accumbens regulate histone deacetylation induced by maternal deprivation and are critical for associated behaviors","volume":"256","author":"Reus","year":"2013","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0640","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0645","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/nbm.1772","article-title":"13C MRS studies of neuroenergetics and neurotransmitter cycling in humans","volume":"24","author":"Rothman","year":"2011","journal-title":"NMR in Biomedicine"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0650","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1176\/appi.ajp.162.2.394","article-title":"Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study","volume":"162","author":"Rowland","year":"2005","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0655","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrn3381","article-title":"The brain reward circuitry in mood disorders","volume":"14","author":"Russo","year":"2013","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0660","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.biopsych.2013.03.032","article-title":"From pathophysiology to novel antidepressant drugs: Glial contributions to the pathology and treatment of mood disorders","volume":"73","author":"Sanacora","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0665","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0670","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/npp.2016.224","article-title":"Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: A randomized, placebo-controlled study","volume":"42","author":"Sanacora","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0675","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/mp.2013.130","article-title":"Lanicemine: A low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects","volume":"19","author":"Sanacora","year":"2014","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0680","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2011.07.036","article-title":"Towards a glutamate hypothesis of depression: An emerging frontier of neuropsychopharmacology for mood disorders","volume":"62","author":"Sanacora","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0685","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/npp.2017.229","article-title":"Multimodal investigation of network level effects using intrinsic functional connectivity, anatomical covariance, and structure-to-function correlations in unmedicated major depressive disorder","volume":"43","author":"Scheinost","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0690","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuron.2013.02.011","article-title":"Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver","volume":"78","author":"Schobel","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0695","first-page":"S111","article-title":"Endogenous kynurenic acid mediates ketamine- and (2R,6R)-hydroxynorketamine-induced increases in extracellular glutamate and antidepressant actions","volume":"43","author":"Schwarcz","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0700","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.urology.2007.01.038","article-title":"Ketamine-associated ulcerative cystitis: A new clinical entity","volume":"69","author":"Shahani","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0705","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1073\/pnas.93.9.3908","article-title":"Hippocampal atrophy in recurrent major depression","volume":"93","author":"Sheline","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0710","doi-asserted-by":"crossref","DOI":"10.1177\/2470547017715645","article-title":"Chronic stress in adolescents and its neurobiological and psychopathological consequences: An RDoC perspective","volume":"1","author":"Sheth","year":"2017","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0715","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0720","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0725","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2007-979537","article-title":"Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression","volume":"29","author":"Skolnick","year":"1996","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0730","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1017\/S1092852916000523","article-title":"Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: A comprehensive meta-analysis of efficacy and safety outcomes in short-term trials","volume":"21","author":"Solmi","year":"2016","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0735","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/mp.2011.171","article-title":"Ketamine effects on brain GABA and glutamate levels with 1H-MRS: Relationship to ketamine-induced psychopathology","volume":"17","author":"Stone","year":"2012","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0740","doi-asserted-by":"crossref","DOI":"10.1177\/2470547017694461","article-title":"Early life stress, mood, and anxiety disorders","volume":"1","author":"Syed","year":"2017","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0745","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/0269881117746901","article-title":"Mapping the central effects of (+\/-)-ketamine and traxoprodil using pharmacological magnetic resonance imaging in awake rats","volume":"32","author":"Tang","year":"2018","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0750","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for social anxiety disorder: A randomized, placebo-controlled crossover trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant actions","volume":"185","author":"Trullas","year":"1990","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0760","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.biopsych.2013.04.025","article-title":"Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses","volume":"74","author":"Voleti","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0765","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0770","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0924-977X(96)00039-9","article-title":"Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0775","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nn.3591","article-title":"Stress and CRF gate neural activation of BDNF in the mesolimbic reward pathway","volume":"17","author":"Walsh","year":"2014","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0780","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/hbm.22241","article-title":"Overlapping and segregated resting-state functional connectivity in patients with major depressive disorder with and without childhood neglect","volume":"35","author":"Wang","year":"2014","journal-title":"Human Brain Mapping"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0785","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000362875","article-title":"Altered gene expression and spine density in nucleus accumbens of adolescent and adult male mice exposed to emotional and physical stress","volume":"36","author":"Warren","year":"2014","journal-title":"Developmental Neuroscience"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0790","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0795","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1172\/JCI85033","article-title":"GABA interneurons mediate the rapid antidepressant-like effects of scopolamine","volume":"126","author":"Wohleb","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0800","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.biopsych.2015.12.009","article-title":"Essential role of mesolimbic brain-derived neurotrophic factor in chronic social stress-induced depressive behaviors","volume":"80","author":"Wook Koo","year":"2016","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0805","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euroneuro.2017.02.010","article-title":"Cortical thickness reduction in combat exposed U.S. veterans with and without PTSD","volume":"27","author":"Wrocklage","year":"2017","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0810","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature25509","article-title":"Ketamine blocks bursting in the lateral habenula to rapidly relieve depression","volume":"554","author":"Yang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0815","doi-asserted-by":"crossref","DOI":"10.1038\/mp.2017.239","article-title":"Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit","author":"Yao","year":"2017","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0820","doi-asserted-by":"crossref","first-page":"14075","DOI":"10.1073\/pnas.0906791106","article-title":"Acute stress enhances glutamatergic transmission in prefrontal cortex and facilitates working memory","volume":"106","author":"Yuen","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0825","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/mp.2010.50","article-title":"Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memory","volume":"16","author":"Yuen","year":"2011","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0830","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.neuron.2011.12.033","article-title":"Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex","volume":"73","author":"Yuen","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0835","doi-asserted-by":"crossref","first-page":"10037","DOI":"10.1073\/pnas.88.22.10037","article-title":"Interplay between glutamate and gamma-aminobutyric acid transmitter systems in the physiological regulation of brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal neurons","volume":"88","author":"Zafra","year":"1991","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0840","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0845","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0850","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.biopsych.2012.10.019","article-title":"A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression","volume":"74","author":"Zarate","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2018.05.010_bb0855","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Archives of General Psychiatry"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818300901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818300901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T04:18:08Z","timestamp":1661314688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725818300901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":172,"alternative-id":["S0163725818300901"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.05.010","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}